Iatrogenic Cushing's Syndrome Induced by Posaconazole | Zendy

B. Pilmis | Zendy; Hélène Coignard-Biehler | Zendy; Vincent Jullien | Zendy; Olivier Hermine | Zendy; Philippe Touraine | Zendy; Marc Lecuit | Zendy; Olivier Lortholary | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Iatrogenic Cushing's Syndrome Induced by Posaconazole

Author(s) -

B. Pilmis,

Hélène Coignard-Biehler,

Vincent Jullien,

Olivier Hermine,

Philippe Touraine,

Marc Lecuit,

Olivier Lortholary

Publication year - 2013

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.00416-13

Subject(s) - posaconazole , cushing syndrome , medicine , intensive care medicine , dermatology , antifungal , itraconazole

Iatrogenic Cushing's syndrome is an undesirable outcome of glucocorticoids treatment. It can be increased by pharmacologic interactions. Glucocorticoid therapy, given in association with ritonavir, and some azole treatments are causes of iatrogenic Cushing's syndrome. We present a patient with common-variable immunodeficiency who received 7 years of itraconazole therapy for bronchial colonization with Aspergillus in combination with inhaled fluticasone without any Cushingoid symptoms. After a switch to posaconazole, the patient developed Cushingoid symptoms.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research